Cowen & Co. analyst Phil Nadeau maintained a Hold rating on Xoma Corp (XOMA) today. The company’s shares opened today at $15.56.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 7.7% and a 48.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Voyager Therapeutics Inc, and Alexion Pharmaceuticals.
Currently, the analyst consensus on Xoma Corp is a Moderate Buy with an average price target of $36.
See today’s analyst top recommended stocks >>
Based on Xoma Corp’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $4.58 million. In comparison, last year the company had a GAAP net loss of $1.32 million.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XOMA in relation to earlier this year. Most recently, in December 2018, James Neal, the CEO of XOMA bought 678 shares for a total of $8,814.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
XOMA Corp. engages in the discovery and development of innovative therapeutics derived from unique platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Berkeley, CA.
